(3R,6R)-1-(tert-butoxycarbonyl)-6-methylpiperidine-3-carboxylic acid | 1253200-91-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (3R,6R)-1-(tert-butoxycarbonyl)-6-methylpiperidine-3-carboxylic acid
• 英文别名: trans-6-Methyl-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester；(3R,6R)-6-methyl-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-3-carboxylic acid
• CAS: 1253200-91-7
• 化学式: C₁₂H₂₁NO₄
• 分子量: 243.303
• InChiKey: TZCMQIKRCZLVQN-RKDXNWHRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3R,6R)-1-(tert-butoxycarbonyl)-6-methylpiperidine-3-carboxylic acid 在 三乙胺 、 氯甲酸甲酯 、 sodium methylate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 84.0h， 生成 (6R)-1-(tert-butoxycarbonyl)-6-methylpiperidine-3-carboxylic acid
  参考文献：
  名称：

  [EN] 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS
  [FR] MODULATEURS DU RÉCEPTEUR MGLUR5 FOURRÉS DE 2-ALKYL PIPÉRIDINES

  摘要：

  本发明涉及2-烷基哌啶类化合物，这些化合物是代谢型谷氨酸受体的正向变构调节剂，特别是mGluR5受体，可用于治疗或预防与谷氨酸功能障碍有关的神经系统和精神疾病，以及代谢型谷氨酸受体参与的疾病。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病中的用途。

  公开号：

  WO2010124055A1
• 作为产物：
  描述：

  (2R,5R)-tert-butyl 5-(hydroxymethyl)-2-methylpiperidine-1-carboxylate 在 sodium hypochlorite 、 sodium chlorite 、 disodium hydrogenphosphate 、 2,2,6,6-四甲基哌啶氧化物 作用下， 以 水 、 乙腈 为溶剂， 反应 9.0h， 以2.68 g的产率得到(3R,6R)-1-(tert-butoxycarbonyl)-6-methylpiperidine-3-carboxylic acid
  参考文献：
  名称：

  [EN] OXAZOLE OREXIN RECEPTOR ANTAGONISTS
  [FR] COMPOSÉS OXAZOLE ANTAGONISTES DES RÉCEPTEURS D'OREXINE

  摘要：

  本发明涉及氧唑化合物，其为促进睡眠的受体拮抗剂。本发明还涉及所述氧唑化合物在潜在治疗或预防涉及促进睡眠的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗涉及促进睡眠的疾病中的用途。

  公开号：

  WO2015018029A1

文献信息

• [EN] OXAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEUR D'OREXINE À BASE D'OXAZOLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015020930A1

  公开（公告）日：2015-02-12

  The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及氧唑化合物，其为促进素受体的拮抗剂。本发明还涉及所述氧唑化合物在潜在的治疗或预防涉及促进素受体的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗涉及促进素受体的疾病中的用途。
• NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：US20160221948A1

  公开（公告）日：2016-08-04

  The present invention provides a compound represented by the following formula (I) or its pharmaceutically acceptable salt: [wherein, R 1 represents optionally substituted C 1-4 alkyl, n shows integer of 1 to 4, R 2 represents optionally substituted C 1-4 alkyl or hydrogen atom, R 3 represents optionally substituted C 1-4 alkyl, R 4a , R 4b , R 4c , and R 4d , similarly or differently, represent optionally substituted C 6-14 aryl, optionally substituted C 1-4 alkyl, or hydrogen atom and the like, A represents optionally substituted C 6-14 aryl or optionally substituted 5 to 11 membered heteroaryl].

  本发明提供了一种由下式(I)表示的化合物或其药用可接受的盐： [其中，R1表示可选地取代的C1-4烷基，n表示1到4的整数，R2表示可选地取代的C1-4烷基或氢原子，R3表示可选地取代的C1-4烷基，R4a、R4b、R4c和R4d，相同或不同，表示可选地取代的C6-14芳基，可选地取代的C1-4烷基，或氢原子等，A表示可选地取代的C6-14芳基或可选地取代的5至11成员的杂芳基]。
• [EN] THIAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES THIAZOLES DES RÉCEPTEURS DE L'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015018027A1

  公开（公告）日：2015-02-12

  The present invention is directed to thiazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the thiazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及噻唑化合物，其为促进睡眠的受体拮抗剂。本发明还涉及所述噻唑化合物在潜在治疗或预防涉及促进睡眠受体的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗涉及促进睡眠受体的疾病中的用途。
• [EN] THIAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEUR D'OREXINE À BASE DE THIAZOLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015020933A1

  公开（公告）日：2015-02-12

  The present invention is directed to thiazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the thiazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及噻唑化合物，其为促进睡眠的受体拮抗剂。本发明还涉及所述噻唑化合物在潜在治疗或预防涉及促进睡眠的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗涉及促进睡眠的疾病中的用途。
• 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS
  申请人：Mercer Swati P.

  公开号：US20120040998A1

  公开（公告）日：2012-02-16

  The present invention is directed to 2-alkylpiperidines which are positive allosteric modulators of metabotropic glutamate receptors, particularly the mGluR5 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及2-烷基哌啶类化合物，其为代谢型谷氨酸受体的正向变构调节剂，特别是mGluR5受体，并且在治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及代谢型谷氨酸受体参与的疾病方面有用。本发明还涉及包含这些化合物的药物组合物和使用这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的这些疾病方面。